Pacer Advisors’s Sutro Biopharma STRO Stock Holding History

Pacer Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-322	Closed	-$73K	–	1548
2021 Q1	$73K	Buy	+322	New	+$76.4K	﹤0.01%	1356

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Pacer Advisors's STRO Position: Q2 2021 in Review

Pacer Advisors sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 322 shares — an estimated $73K sold.

Pacer Advisors first reported a position in STRO in Q1 2021 and held it in 1 quarter. The position peaked at $73K in Q1 2021. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

Pacer Advisors reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 322 Sutro Biopharma shares in Q2 2021, an estimated $73K.
Pacer Advisors first reported a position in Sutro Biopharma in Q1 2021 and held it in 1 quarter.
Pacer Advisors's Sutro Biopharma position peaked at $73K in Q1 2021.
124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.